Cannabinoid Receptor I (CNR1) Human shRNA Lentiviral Particle (Locus ID 1268)

CAT#: TL316500V

CNR1 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml.

Product Images

GFP signal was observed under microscope at 48 hours after transduction of TL316500A virus into HEK293 cells. TL316500A virus was prepared using lenti-shRNA TL316500A and TR30037 packaging kit.

• 

  GFP signal was observed under microscope at 48 hours after transduction of TL316500B virus into HEK293 cells. TL316500B virus was prepared using lenti-shRNA TL316500B and TR30037 packaging kit.

• 

  GFP signal was observed under microscope at 48 hours after transduction of [TL316500C] virus into HEK293 cells. [TL316500C] virus was prepared using lenti-shRNA [TL316500C] and TR30037 packaging kit.

• 

  GFP signal was observed under microscope at 48 hours after transduction of [TL316500D] virus into HEK293 cells. [TL316500D] virus was prepared using lenti-shRNA [TL316500D] and TR30037 packaging kit.

Specifications

Product Data

• Locus ID: 1268
• Synonyms: CANN6; CB-R; CB1; CB1A; CB1K5; CB1R; CNR
• Vector: pGFP-C-shLenti
• Format: Lentiviral particles
• RefSeq: NM_001160226, NM_001160258, NM_001160259, NM_001160260, NM_001840, NM_016083, NM_033181, NM_016083.3, NM_016083.4, NM_033181.1, NM_033181.2, NM_033181.3, NM_001160226.1, NM_001160258.1, NM_001160259.1, NM_001160260.1, BC074811, BC074812, BC095513, BC100968, BC100969, BC100970, BC100971, BM682178, NM_001365872, NM_001370545, NM_001365869, NM_001365870, NM_001365874, NM_001370546, NM_001370547, NM_001160259.3, NM_001160258.3, NM_016083.6, NM_001160226.3
• UniProt ID: P21554
• Summary: This gene encodes one of two cannabinoid receptors. The cannabinoids, principally delta-9-tetrahydrocannabinol and synthetic analogs, are psychoactive ingredients of marijuana. The cannabinoid receptors are members of the guanine-nucleotide-binding protein (G-protein) coupled receptor family, which inhibit adenylate cyclase activity in a dose-dependent, stereoselective and pertussis toxin-sensitive manner. The two receptors have been found to be involved in the cannabinoid-induced CNS effects (including alterations in mood and cognition) experienced by users of marijuana. Multiple transcript variants encoding two different protein isoforms have been described for this gene. [provided by RefSeq, May 2009]
• shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service.
• Performance Guaranteed: OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.
  
  For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).